NCT06372223View on ClinicalTrials.gov

A Food Effect Study of SPH5030 Tablets.

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 4, 2024

Primary Completion Date

March 25, 2024

Study Completion Date

March 25, 2024

Conditions
Advanced Solid Tumor
Interventions
DRUG

SPH5030

SPH5030 tablets：400mg,orally, Dosing in the fasted state followed by fed dosing.

DRUG

SPH5030

SPH5030 tablets：400mg, orally, Dosing in the fed state followed by fasted dosing.

Trial Locations (1)

Unknown

West China Second Hospital ,Sichuan University, Chengdu

All Listed Sponsors
lead

Shanghai Pharmaceuticals Holding Co., Ltd

INDUSTRY

NCT06372223 - A Food Effect Study of SPH5030 Tablets. | Biotech Hunter | Biotech Hunter